Medtronic‘s AdaptiveStim with RestoreSensor neurostimulation system has been found to be more effective at treating chronic back or leg pain than conventional stimulation.

The study involved 79 patients at ten centres in the US, and 76 patients received implants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, 86.5% of study participants with chronic pain, who were included in an intent-to-treat analysis (n=74), reported pain relief.

During the multicentre, prospective, open-label and randomised, crossover study, 80.3% subjects also reported functional improvements, including improved comfort during position changes.

The patients were randomised to receive either stimulation from the RestoreSensor solution for six weeks with the AdaptiveStim technology switched on followed by six weeks with AdaptiveStim switched off, or six weeks with AdaptiveStim turned off followed by six weeks with AdaptiveStim turned on.

According to physicians, 88.7% of participants reported clinical benefits from the system, which uses motio-sensor technology to provide pain relief.

The system also helps clinicians in understanding how a patient’s stimulation requirements are changing over time.

Trial investigator David Schultz said that the study "clearly demonstrates the effectiveness of position-adaptive stimulation technology in providing pain relief and convenience to patients suffering from chronic pain, so they can lead more normal lives".

The US Food and Drug Administration approved the AdaptiveStim with RestoreSensor for the management of chronic pain.